Amphastar Pharmaceuticals (AMPH) Total Debt Growth (3y) (2016 - 2026)
Amphastar Pharmaceuticals (AMPH) Total Debt Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 15.43% |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -7.08% |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 11.33% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -3.67% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -10.43% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | -13.72% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 92.83% |
| 10 | Amphastar Pharmaceuticals | 937.87 Mn | 647.74 Mn | 93.47 Mn | 6.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.89% |
| Mar 31, 2026 | 101.23% |
| Dec 31, 2025 | 100.36% |
| Sep 30, 2025 | 100.44% |
| Jun 30, 2025 | 100.13% |
| Mar 31, 2025 | 99.13% |
| Dec 31, 2024 | 98.48% |
| Sep 30, 2024 | 97.20% |
| Jun 30, 2024 | 147.90% |
| Mar 31, 2024 | 137.26% |
| Dec 31, 2023 | 133.33% |
| Sep 30, 2023 | 141.99% |
| Mar 31, 2023 | 16.17% |
| Dec 31, 2022 | 17.20% |
| Sep 30, 2022 | 18.88% |
| Jun 30, 2022 | 17.56% |
| Mar 31, 2022 | 16.36% |
| Dec 31, 2021 | 15.31% |
| Sep 30, 2021 | 14.97% |
| Jun 30, 2021 | -9.84% |